Kim Bu Kyung, Seo Kyung Won
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
Department of Surgery, Kosin University College of Medicine, Busan, Korea.
J Metab Bariatr Surg. 2022 Dec;11(2):13-19. doi: 10.17476/jmbs.2022.11.2.13. Epub 2022 Dec 30.
Recently, metabolic surgery was recommended for patients with a BMI of 30 or higher and 27.5 or higher for Asians, as evidence level A. Until 2008, bariatric surgery was not introduced for the treatment of diabetes. Bariatric surgery was first recommended for adults with body mass index ≥35 kg/m and type 2 diabetes in the American Diabetes Association (ADA) guidelines as evidence level B in 2009. In 2017, the terminology was changed from bariatric surgery to metabolic surgery. How such large changes could have occurred in the ADA guidelines? Because many patients have reached diabetes remission through metabolic surgery, and the long-term benefit and cost-effectiveness have been strongly proven by historical randomized controlled trials and high-quality studies. This review demonstrates how the recommendations for the treatment of obesity in patients with diabetes have changed in diabetes treatment guidelines and summarizes the evidence behind this change.
最近,代谢手术被推荐用于体重指数(BMI)为30及以上的患者,亚洲患者的BMI为27.5及以上时也适用,证据等级为A。直到2008年,减重手术才被引入用于治疗糖尿病。2009年,美国糖尿病协会(ADA)指南首次推荐将减重手术用于体重指数≥35kg/m²的成年2型糖尿病患者,证据等级为B。2017年,术语从减重手术改为代谢手术。ADA指南中怎么会发生如此巨大的变化呢?因为许多患者通过代谢手术实现了糖尿病缓解,并且长期益处和成本效益已被既往的随机对照试验和高质量研究有力证实。本综述展示了糖尿病治疗指南中糖尿病患者肥胖治疗建议是如何变化的,并总结了这一变化背后的证据。